An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

Adjuvant Setting ◽

Her2 Positive ◽

Open Label ◽

Safety And Efficacy ◽

Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

The Breast ◽

10.1016/s0960-9776(17)30116-9 ◽

2017 ◽

Vol 32 ◽

pp. S27

Author(s):

S. Talayeva ◽

D. Kaidarova ◽

E. Zhavrid ◽

A. Prokharau ◽

N. Antonenkova ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health ◽

10.4274/ejbh.galenos.2021.2021-9-9 ◽

2022 ◽

Vol 18 (1) ◽

pp. 63-73

Author(s):

İrfan Cicin ◽

Mohammed Oukkal ◽

Hassen Mahfouf ◽

Amel Mezlini ◽

Blaha Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Patient Satisfaction ◽

Early Breast Cancer ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2334 ◽

2020 ◽

Vol 31 ◽

pp. S330

Author(s):

A.J. ten Tije ◽

S. van Steenis ◽

J. Briers ◽

E.M.P. Elsten

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Injection Device ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase ◽

Single Use ◽

At Home

1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study

European Journal of Cancer ◽

10.1016/s0959-8049(12)70068-0 ◽

2012 ◽

Vol 48 ◽

pp. S37 ◽

Cited By ~ 3

Author(s):

C. Jackisch ◽

D. Stroyakovskiy ◽

S. Muehlbauer ◽

D. Heinzmann ◽

M.V. Kopp ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Open Label

Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

10.1158/1538-7445.sabcs19-pd4-07 ◽

2020 ◽

Author(s):

Antoinette R Tan ◽

Seock-Ah Im ◽

Andre Mattar ◽

Ramon Colomer ◽

Daniil Stroyakovskii ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Primary Analysis ◽

Her2 Positive ◽

Open Label ◽

Dose Combination

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05604-7 ◽

2020 ◽

Vol 181 (1) ◽

pp. 97-105 ◽

Cited By ~ 2

Author(s):

Hannelore Denys ◽

Corina L. Martinez-Mena ◽

Marc T. Martens ◽

Randal G. D’Hondt ◽

Marie-Pascale L. Graas ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Home Administration ◽

At Home

Abstract P1-10-01: Safety and efficacy of neoadjuvant metformin with trastuzumab and chemotherapy in women with HER2-positive early breast cancer: A randomized, open-label, multicenter, phase 2 trial

10.1158/1538-7445.sabcs17-p1-10-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

S Pernas ◽

J Dorca ◽

I Álvarez-López ◽

S Martínez ◽

C Saura ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Multicenter Phase

An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies

Annals of Oncology ◽

10.1093/annonc/mdw364.66 ◽

2016 ◽

Vol 27 ◽

pp. vi63

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Early Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase Iiib ◽

Cancer Studies

The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

European Journal of Cancer ◽

10.1016/s0959-8049(18)30542-2 ◽

2018 ◽

Vol 92 ◽

pp. S105-S106

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Early Breast Cancer ◽

Safety Data ◽

Metastatic Breast ◽

Pooled Analysis ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04024462 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Her2 Positive ◽

Dose Combination